Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and programmed cell death (PD)-1 receptor and its ligands (PD-L1, PD-L2) suppress the activity of T-lymphocyte...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmacogenomics and personalized medicine Vol. 7; no. default; pp. 357 - 365
Main Authors:	Postow, Michael, Momtaz, Parisa
Format:	Journal Article
Language:	English
Published:	New Zealand Dove Medical Press Limited 01.01.2014 Taylor & Francis Ltd Dove Medical Press
Subjects:	Antigens Apoptosis Biomarkers Cancer Cancer therapies Care and treatment Cell death Cytokines Cytotoxicity Dendritic cells FDA approval Genetic aspects Health aspects Homeostasis Immune checkpoint Immune system Immunotherapy Innovations Ligands Lymphocytes Lymphoma Melanoma Metastasis Monoclonal antibodies PD-1 protein PD-L1 protein Review Skin cancer Targeted cancer therapy Vaccines New York United States > US programmed cell death protein-1 cytotoxic T-lymphocyte antigen 4 immunotherapy immune checkpoints
ISSN:	1178-7066, 1178-7066
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!